SCHEMBL192399

SCHEMBL192399

O=Cc1ccccc1/C=C/c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
THRB P10828 1/20 0.62
BLM P54132 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
NFE2L2 Q16236 4/20 0.56
TRPA1 O75762 3/20 0.56
ALDH1A1 P00352 4/20 0.52
CYP2A6 P11509 1/20 0.52
ALOX5 P09917 1/20 0.50
MAPK1 P28482 1/20 0.50
MAOB P27338 2/20 0.46
CYP19A1 P11511 1/20 0.44
MAOA P21397 1/20 0.44
TSHR P16473 1/20 0.44
TRIM24 O15164 1/20 0.44
TRIM33 Q9UPN9 1/20 0.44
DPYD Q12882 1/20 0.44
HDAC3 O15379 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30958792 1.00 LMNA (0.62) LMNAMEN1KMT2ATHRBBLM
SCHEMBL192400 1.00 LMNA (0.62) LMNAMEN1KMT2ATHRBBLM
SCHEMBL24385991 1.00 LMNA (0.62) LMNAMEN1KMT2ATHRBBLM
(Z)-1,2-Diphenylethene SCHEMBL7653143 0.87 NFE2L2 (0.68) MEN1KMT2ANFE2L2TRPA1MAOB
SCHEMBL44502 0.87 NFE2L2 (0.68) MEN1KMT2ANFE2L2TRPA1MAOB
SCHEMBL6360540 0.87 NFE2L2 (0.68) MEN1KMT2ANFE2L2TRPA1MAOB
SCHEMBL44503 0.87 NFE2L2 (0.68) MEN1KMT2ANFE2L2TRPA1MAOB
(Z)-1,2-Diphenylethene SCHEMBL7653150 0.87 NFE2L2 (0.68) MEN1KMT2ANFE2L2TRPA1MAOB
SCHEMBL9540538 0.87 NFE2L2 (0.68) MEN1KMT2ANFE2L2TRPA1MAOB
SCHEMBL5411617 0.87 NFE2L2 (0.68) MEN1KMT2ANFE2L2TRPA1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337229-B1 IMMOBILISATION OF ACTIVE AGENTS ON FIBRES HENKEL AG & CO KGAA (DE) 2009-09-30 EP claimed
EP-1337229-A2 IMMOBILISATION OF ACTIVE AGENTS ON FIBRES Henkel Kommanditgesellschaft auf Aktien (DE) 2003-08-27 EP claimed
WO-2002043675-A2 IMMOBILISATION OF ACTIVE AGENTS ON FIBRES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2002-06-06 WO claimed
EP-1210476-A1 MIXTURES OF FLUORESCENT WHITENING AGENTS Ciba SC Holding AG (CH) 2002-06-05 EP claimed
WO-2001018301-A1 MIXTURES OF FLUORESCENT WHITENING AGENTS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2001-03-15 WO claimed
US-10483468-B2 Compound and organic electronic device using the same SHANGHAI NICHEM FINE CHEMICAL CO., LTD. (CN) 2019-11-19 US disclosed
US-20180159045-A1 COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME NICHEM FINE TECHNOLOGY CO., LTD. (TW) 2018-06-07 US disclosed
EP-3328846-A1 NOVEL COMPOUNDS EXHIBITING PHOTOPHYSICAL PROPERTIES UPON FORMATION OF LEWIS ACID-BASE ADDUCTS USING NON-CHELATING BORANES, METHOD FOR PRODUCING THE SAME AND DEVICES INCLUDING THE SAME Universität Heidelberg (DE) 2018-06-06 EP disclosed
WO-2017016653-A1 NOVEL COMPOUNDS EXHIBITING PHOTOPHYSICAL PROPERTIES UPON FORMATION OF LEWIS ACID-BASE ADDUCTS USING NON-CHELATING BORANES, METHOD FOR PRODUCING THE SAME AND DEVICES INCLUDING THE SAME Universität Heidelberg (DE) 2017-02-02 WO disclosed
WO-2017016653-A1 NOVEL COMPOUNDS EXHIBITING PHOTOPHYSICAL PROPERTIES UPON FORMATION OF LEWIS ACID-BASE ADDUCTS USING NON-CHELATING BORANES, METHOD FOR PRODUCING THE SAME AND DEVICES INCLUDING THE SAME Universität Heidelberg (DE) 2017-02-02 WO disclosed
US-8552220-B2 Therapeutic agent for Alzheimer's disease TOKYO INSTITUTE OF TECHNOLOGY (JP) 2013-10-08 US disclosed
US-8349870-B2 Fungicidal hetercyclic compounds E I DU PONT DE NEMOURS AND COMPANY (US) 2013-01-08 US disclosed
WO-2001018301-A1 MIXTURES OF FLUORESCENT WHITENING AGENTS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2001-03-15 WO disclosed
EP-0763015-A1 SYSTEMATIC MODULAR PRODUCTION OF AMINIMIDE- AND OXAZOLONE- BASED MOLECULES HAVING AT LEAST TWO STRUCTURAL DIVERSITY ELEMENTS ARQULE, INC. (US) 1997-03-19 EP disclosed
WO-1995032184-A1 SYSTEMATIC MODULAR PRODUCTION OF AMINIMIDE- AND OXAZOLONE- BASED MOLECULES HAVING AT LEAST TWO STRUCTURAL DIVERSITY ELEMENTS ARQULE, INC. (US) 1995-11-30 WO disclosed
EP-0245918-B1 1,4-DIHYDROPYRIDINE DERIVATIVES GLAXO S.p.A. (IT) 1993-05-05 EP disclosed
US-4946851-A 1.4-dihydropyridines GLAXO, S.P.A. (IT) 1990-08-07 US disclosed
EP-0245918-A1 1,4-Dihydropyridine derivatives GLAXO S.p.A. (IT) 1987-11-19 EP disclosed
EP-0238446-A1 Mixtures of optical brighteners CIBA-GEIGY AG (CH) 1987-09-23 EP disclosed
US-4271186-A Stilbene compounds and insecticidal/acaricidal compositions BAYER AKTIENGESELLSCHAFT (DE) 1981-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10483468-B2 Compound and organic electronic device using the same ORC3, RBX1, CBX3 LMNA 4414/4885MEN1 1725/4885KMT2A 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.